Lucentis is the second anti-VEGF drug FDA approved for the treatment of wet macular degeneration. It is an effective treatment for wet macular degeneration. The formulation differs from Macugen and Avastin as do the visual results.
Pan-retinal laser photocoagulation has been the gold-standard treatment for proliferative diabetic retinopathy. Avastin injections may become a safer, better alternative to retinal laser treatment to prevent blindness.